

Mouse Anti-HLA-A (MHC I) [C6]: MC0126

Intended Use: For Research Use Only

Description: HLA-A, with HLA-B and HLA-C, belongs to major histocompatibility complex (MHC) class I antigens and expresses constitutively on all nucleated cells. MHC class I antigens play a role in class I MHC-associated antigen presentation, inhibition of NK cell cytotoxicity, tumor surveillance, and tissue allotransplantation. This antibody is useful for HLA molecular typing of peripheral blood leukocytes as well as a large number of leukemic cell lines. It reacts with an intralocus determinant present on a limited number of HLA-A locus-encoded gene products (HLA-A2, -A3, -A28, -A29, -A30, -A31 and -Aw33). Its epitope maps between aa65-to-aa80 of the 1 domain of the HLA-A. This antibody recognizes an intralocus determinant present on a limited number of HLA-A locus-encoded gene products (HLA-A2, -A3, A28, -A29, -A30, -A31 and -Aw33). Furthermore, by testing its reactivity with HLA-A2 natural variants and mutants, the importance of amino acid residues 79 and/or 80 of the $\alpha 1$ domain was demonstrated in the formation of an intralocus HLA-A determinant.


Specifications:

Clone: C6
 Source: Mouse
 Isotype: IgG2b/k
 Reactivity: Human
 Localization: Membrane, cytoplasm
 Formulation: Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN₃)
 Storage: Store at 2°- 8°C
 Applications: IHC, ELISA, ICC/IF, IP, WB
 Package:

Description	Catalog No.	Size
HLA-A (MHC I) [C6] Concentrated	MC0126	1 ml

IHC Procedure*:

Positive Control Tissue: IHC: tonsil, Zebrafish xenograft. ICC/IF: MCF7 and Raji cells. WB: THP-1, A549, HL-60 and Raji cell lysate. IP: THP-1 and A549 cell lysate. Flow Cyt.: Raji cells.
 Concentrated Dilution: 50-200
 Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual
 * Result should be confirmed by an established diagnostic procedure.



FFPE human spleen stained with anti-HLA-A using DAB

References:

1. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Johnson DB, et al. Nat Commun. Jan 29;7:10582, 2016.
2. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Loi S, et al. Clin Cancer Res. Mar 15;22(6):1499-509, 2016.

Doc. 100-MC0126
Rev. A